Cns Pharmaceuticals Stock Buy Hold or Sell Recommendation

CNSP Stock  USD 2.43  0.01  0.41%   
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cns Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Cns Pharmaceuticals within the specified time frame.
  
Check out Cns Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.
Note, we conduct extensive research on individual companies such as Cns and provide practical buy, sell, or hold advice based on investors' constraints. Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Execute Cns Pharmaceuticals Buy or Sell Advice

The Cns recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cns Pharmaceuticals. Macroaxis does not own or have any residual interests in Cns Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cns Pharmaceuticals' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Cns PharmaceuticalsBuy Cns Pharmaceuticals
Strong Sell

Market Performance

Very WeakDetails

Volatility

Abnormally volatileDetails

Hype Condition

Under hypedDetails

Current Valuation

OvervaluedDetails

Odds Of Distress

Very HighDetails

Economic Sensitivity

Moves slightly opposite to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon Cns Pharmaceuticals has a Mean Deviation of 4.96, Standard Deviation of 8.18 and Variance of 66.95
We provide trade advice to complement the prevailing expert consensus on Cns Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Cns Pharmaceuticals is not overpriced, please confirm all Cns Pharmaceuticals fundamentals, including its cash flow from operations, and the relationship between the cash per share and beta . Please also double-check Cns Pharmaceuticals price to earning to validate your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Cns Pharmaceuticals Trading Alerts and Improvement Suggestions

Cns Pharmaceuticals generated a negative expected return over the last 90 days
Cns Pharmaceuticals has high historical volatility and very poor performance
Cns Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0.
Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Cns Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Mahery Amy of 17500 shares of Cns Pharmaceuticals at 0.2586 subject to Rule 16b-3

Cns Pharmaceuticals Returns Distribution Density

The distribution of Cns Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Cns Pharmaceuticals' future price movements. The chart of the probability distribution of Cns Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Cns Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cns Pharmaceuticals returns is essential to provide solid investment advice for Cns Pharmaceuticals.
Mean Return
-1.11
Value At Risk
-10.84
Potential Upside
8.74
Standard Deviation
8.18
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cns Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Cns Stock Institutional Investors

The Cns Pharmaceuticals' institutional investors refer to entities that pool money to purchase Cns Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
Shares
Bank Of America Corp2024-12-31
440
Sbi Securities Co Ltd2024-12-31
105
Synergy Investment Management, Llc2024-12-31
9.0
Wells Fargo & Co2024-12-31
4.0
Global Retirement Partners, Llc.2024-09-30
2.0
Parallel Advisors, Llc2024-09-30
0.0
Tower Research Capital Llc2024-12-31
0.0
Northern Trust Investments N A2024-12-31
0.0
Fmr Inc2024-09-30
0.0
Jane Street Group Llc2024-12-31
419.7 K
Geode Capital Management, Llc2024-12-31
387.1 K
Note, although Cns Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cns Pharmaceuticals Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash6.8M(9.0M)5.1M(9.5M)(8.6M)(8.1M)
Net Borrowings886.7K(35K)(88.1K)(477.5K)(429.7K)(408.3K)
Depreciation11.1K13.1K11.8K4.1K4.8K7.2K
Capital Expenditures17.9K5.7K4.4K3.9K3.5K3.3K
Net Income(9.5M)(14.0M)(15.3M)(18.9M)(17.0M)(16.1M)
End Period Cash Flow14.0M5.0M10.1M548.7K631.0K599.5K
Change To Netincome6.6M627.1K1.3M1.7M1.6M1.7M
Free Cash Flow(7.3M)(13.5M)(10.6M)(14.1M)(12.7M)(13.4M)
Other Non Cash Items1.6K714.9K337.2K498.0448.2425.79
Investments(17.9K)(5.7K)(4.4K)(1.7K)(2.0K)(2.1K)

Cns Pharmaceuticals Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cns Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cns Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cns stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-1.13
β
Beta against Dow Jones-0.57
σ
Overall volatility
8.53
Ir
Information ratio -0.13

Cns Pharmaceuticals Volatility Alert

Cns Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cns Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cns Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Cns Pharmaceuticals Fundamentals Vs Peers

Comparing Cns Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cns Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Cns Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cns Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cns Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cns Pharmaceuticals by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Cns Pharmaceuticals to competition
FundamentalsCns PharmaceuticalsPeer Average
Return On Equity-10.19-0.31
Return On Asset-2.24-0.14
Current Valuation(3.33 M)16.62 B
Shares Outstanding40.75 M571.82 M
Shares Owned By Insiders1.20 %10.09 %
Shares Owned By Institutions0.70 %39.21 %
Number Of Shares Shorted3.93 M4.71 M
Price To Earning(13.70) X28.72 X
Price To Book1.08 X9.51 X
EBITDA(18.86 M)3.9 B
Net Income(18.85 M)570.98 M
Cash And Equivalents8.96 M2.7 B
Cash Per Share0.22 X5.01 X
Total Debt300.81 K5.32 B
Debt To Equity0.01 %48.70 %
Current Ratio12.34 X2.16 X
Book Value Per Share(2.98) X1.93 K
Cash Flow From Operations(14.14 M)971.22 M
Short Ratio0.04 X4.00 X
Earnings Per Share(352.97) X3.12 X
Target Price0.5
Number Of Employees318.84 K
Beta1.05-0.15
Market Capitalization5.28 M19.03 B
Total Asset1.7 M29.47 B
Retained Earnings(69.57 M)9.33 B
Working Capital(4.54 M)1.48 B
Current Asset6.61 M9.34 B
Current Liabilities488.66 K7.9 B
Net Asset1.7 M
Note: Acquisition by Mahery Amy of 17500 shares of Cns Pharmaceuticals at 0.2586 subject to Rule 16b-3 [view details]

Cns Pharmaceuticals Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cns . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Cns Pharmaceuticals Buy or Sell Advice

When is the right time to buy or sell Cns Pharmaceuticals? Buying financial instruments such as Cns Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Cns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.